Project Grant R01HL179266
Award Date 7/1/26
Completion Date 3/31/29
Dollars Obligated $718K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
West Hollywood, CA 90048, USA
Similar Awards
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Cedars-Sinai Medical Center a Project Grant totaling $497,998 beginning September 1, 2025, and concluding August 31, 2028, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds basic research investigating the nature and regulation of extramedullary hematopoiesis (EMH) in the liver, with focus on understanding how hematopoietic stem cells (HSCs) initiate blood cell production...
- Federal Grant Award Summary Cedars-Sinai Medical Center received a $694,252 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 15, 2025, with completion targeted for June 30, 2030. The award funds research into the mechanisms of cardioprotective Y RNA (YRNA) signaling in macrophages to enhance therapeutic outcomes following myocardial infarction. The research focuses on understanding how a...
- Federal Grant Award Summary Award Details: Cedars-Sinai Medical Center received a $1,214,851 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 20, 2025, with completion targeted for May 31, 2029. Research Scope and Deliverables: The grant funds investigation of nuclear transport mechanisms for SMAD signaling proteins, which are critical developmental effectors in left-right axis formation...
- Federal Project Grant Award Summary Award Overview Cedars-Sinai Medical Center received a $300,000 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Trans-NIH Research Support program (CFDA 93.310) effective July 8, 2026, with a completion date of April 30, 2031. This award supports therapeutic preclinical development of TY1, a novel synthetic noncoding RNA (ncRNA) drug candidate designed to treat scleroderma-associated systemic sclerosis (SSC) cardiomyopathy....
- Federal Project Grant Award Summary Cedars-Sinai Medical Center received a $256,650 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective July 2, 2026, with a completion date of June 30, 2028. The project, titled "ISG15 Monocytes as Precursors to SPP1 Macrophages in Scleroderma ILD," will deliver mechanistic research and biomarker discovery services focused on...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant of $873,801 to Icahn School of Medicine at Mount Sinai, effective June 1, 2026, through February 28, 2031, under the Cardiovascular Diseases Research program (CFDA 93.837). This award funds basic and translational research investigating epithelial reprogramming mechanisms that distinguish normal (euplastic) versus abnormal (dysplastic) lung repair processes. The research aims to...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Feinstein Institutes for Medical Research a Project Grant of $586,866 under the Cardiovascular Diseases Research program (CFDA 93.837) on May 15, 2026, with a completion date of February 28, 2030. This award funds research investigating the critical role of B-1A cells, an immunoregulatory B cell subset, in mitigating acute lung injury (ALI) and acute respiratory distress...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the Regents of the University of California, San Francisco a Project Grant of $1,097,760 (obligated February 15, 2026) under the Cardiovascular Diseases Research program (CFDA 93.837) to support a research initiative addressing age-related pulmonary fibrosis and lung regeneration through December 31, 2032. The research program will investigate the cellular and molecular mechanisms driving idiopathic...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $163,836 Project Grant to The Regents of the University of California, San Francisco on July 8, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). This K08 career development award funds a five-year research project (through June 30, 2031) investigating bidirectional signaling networks in pulmonary silicosis, a progressive fibrotic lung disease characterized by granuloma formation....
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Regents of the University of California, San Francisco a Project Grant of $182,060 under the Cardiovascular Diseases Research program (CFDA 93.837) for research investigating the role of the senescence marker P16INK4A in alveolar epithelial stem cells during injury-triggered differentiation. The award, obligated on September 30, 2025, with a completion date of November 29, 2026, supports...